Rheumatoid Arthritis Posts - Page 3 of 34 on Medivizor
Navigation Menu

Rheumatoid Arthritis Posts on Medivizor

Interleukin-6 levels predict greater improvement of quality of life with sarilumab than with adalimumab in patients with RA

Interleukin-6 levels predict greater improvement of quality of life with sarilumab than with adalimumab in patients with RA

Posted by on Feb 7, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study examined the effect of sarilumab (Kevzara) compared to adalimumab (Humira) on health-related quality of life (HRQoL) based on inflammatory marker levels in patients with rheumatoid arthritis (RA).  The data showed that sarilumab has a higher effect on improving aspects of HRQoL in patients...

Read More

Switching between upadacitinib and adalimumab offers benefits in patients with unresponsive rheumatoid arthritis.

Switching between upadacitinib and adalimumab offers benefits in patients with unresponsive rheumatoid arthritis.

Posted by on Dec 20, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of switching from upadacitinib (UPA; Rinvoq) to adalimumab (ADA; Humira) and from ADA to UPA following insufficient response in patients with rheumatoid arthritis (RA). The authors found that patients who do not respond to UPA or ADA can be...

Read More

Does rheumatoid arthritis treatment affect the risk of cardiovascular disease?

Does rheumatoid arthritis treatment affect the risk of cardiovascular disease?

Posted by on Dec 18, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effect of disease-modifying anti-rheumatic drugs (DMARDs) on cardiovascular disease (CVD) risk. They found that abatacept (Orencia) and tumor necrosis factor inhibitors (TNFi) were associated with decreased CVD risk. Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by...

Read More

What is the risk of infection with biological and targeted therapeutics in rheumatoid arthritis?

What is the risk of infection with biological and targeted therapeutics in rheumatoid arthritis?

Posted by on Dec 13, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study reviewed infection risk in patients treated with biologic and targeted disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by painful inflammation in the joints. RA is treated with drugs to reduce...

Read More

Certolizumab pegol in rheumatoid arthritis: a 3-year update on safety and effectiveness

Certolizumab pegol in rheumatoid arthritis: a 3-year update on safety and effectiveness

Posted by on Dec 6, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the long-term effectiveness and safety of certolizumab pegol (Cimzia) in patients with rheumatoid arthritis (RA) from a real-world practice. They found that this medication was safe and patients had a sustained response.  Some background Rheumatoid arthritis (RA) is a chronic condition. It is...

Read More

Is the neutrophil-to-lymphocyte ratio a useful indicator of bacterial infection in patients with RA treated with tocilizumab?

Is the neutrophil-to-lymphocyte ratio a useful indicator of bacterial infection in patients with RA treated with tocilizumab?

Posted by on Nov 15, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the neutrophil-to-lymphocyte ratio (NLR) as an indicator of infection in patients with rheumatoid arthritis (RA) treated with tocilizumab (Actemra). They found that the NLR is an accurate indicator of infection in these patients.  Some background Rheumatoid arthritis (RA) is a chronic condition. It...

Read More

Do biological DMARDs affect diabetes risk in patients with rheumatoid arthritis?

Do biological DMARDs affect diabetes risk in patients with rheumatoid arthritis?

Posted by on Nov 13, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if biological disease-modifying anti-rheumatic drugs (bDMARDs) affect diabetes risk in patients with rheumatoid arthritis (RA). They found that bDMARD use was associated with lower rates of diabetes in these patients.  Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by...

Read More

Do weight changes increase the risk of cardiovascular events in patients with rheumatoid arthritis?

Do weight changes increase the risk of cardiovascular events in patients with rheumatoid arthritis?

Posted by on Nov 6, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if weight changes increase the risk of cardiovascular events (CVEs) in patients with rheumatoid arthritis (RA). They found that a 10% increase or decrease in weight increased the risk of CVEs in these patients.  Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused...

Read More